Can measurement of apolipoprotein B replace the lipid profile in the follow-up of patients with lipoprotein disorders?

Clinical Chemistry

Volumn 48, Issue 3, 2002, Pages 401-402

  Durrington, Paul N ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; VERY LOW DENSITY LIPOPROTEIN;

CORONARY RISK; DIAGNOSTIC VALUE; EDITORIAL; EPITOPE MAPPING; FOLLOW UP; GENE MUTATION; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOASSAY; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN DEFICIENCY; LIPOPROTEIN METABOLISM; MATHEMATICAL COMPUTING; PROTEIN STRUCTURE; RECEPTOR BINDING; VALIDATION PROCESS;

EID: 0036179263     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/48.3.401     Document Type: Editorial

References (18)

1. Plasma lipoproteins and apolipoproteins
2. Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins
3. Serum and lipoprotein apolipoprotein B levels in normal subjects and patients with hyperlipoproteinaemia
4. Association of hyperapo-β-lipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis
5. Primary hypertriglyceridemia with borderline high cholesterol and increased apolipoprotein B concentrations
6. Role of oxidized low density lipoprotein in atherogenesis
7. Recent progress in defining the role of scavenger receptors in lipid transport, atherosclerosis and host defence
8. Measurement of apolipoproteins: Time to improve the diagnosis and treatment of the atherogenic dyslipoproteinemias
9. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions. Relative contribution of small dense LDL to coronary heart disease risk
10. Measurement and clinical significance of apolopoproteins A-1 and B
11. Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders?
12. Statin trials and goals of cholesterol lowering therapy
13. Thrombogenic factors and recurrent coronary events
14. Apolipoprotein concentrations during treatment and recurrent coronary events
15. Relation between baseline and on-treatment lipid parameters and first acute coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
16. The Friedewald formula underestimates LDL cholesterol at low concentrations
17. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIB hyperlipoproteinaemia
18. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)